Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

U.S. racing to send aid to India as COVID-19 cases soar

Published 04/25/2021, 01:05 AM
Updated 04/25/2021, 01:06 AM
© Reuters. Outbreak of the coronavirus disease (COVID-19) in New Delhi

By Andrea Shalal

WILMINGTON, Del. (Reuters) -The United States is deeply concerned by a massive surge in coronavirus cases in India and will race additional support to the Indian government and health care workers, a White House spokeswoman said on Saturday.

"We are in active conversations at high levels and plan to quickly deploy additional support to the Government of India and Indian health care workers as they battle this latest severe outbreak. We will have more to share very soon," the spokeswoman told Reuters via email.

Washington is under increasing pressure to do more to help India, the world's largest democracy and a strategic ally in President Joe Biden's efforts to counter China, as it grapples with a record-setting surge in coronavirus infections.

The Indian government has deployed military planes and trains to get urgently needed oxygen to Delhi from other parts of the country and foreign countries, including Singapore.

The number of cases across the country surged by a record daily rise of 349,691 on Sunday, for a total of 16.96 million cases, including 192,311 deaths, the health ministry said.

The country of 1.3 billion people is on the brink of a humanitarian catastrophe, Ashish Jha, dean of the Brown University School of Public Health, warned in an op-ed published Saturday in the Washington Post.

He said some 2,000 people were dying daily, but most experts estimated that the true number was five to 10 times that level.

Officials from both countries are engaged at various levels to ensure "a small supply of inputs and components from U.S. companies for production of COVID-19 vaccines in India," a spokesman at the Indian Embassy in Washington told Reuters.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

He said it was important to work together to identify ways to overcome bottlenecks in medical supply chains and expedite ongoing vaccination efforts.

Jha called on Washington to send India oxygen, excess testing kits and high-quality personal protective equipment, including face masks, and medicines to treat COVID-19 patients, including sedatives and Remdesivir.

Jha also urged the Biden administration to share excess vaccines with India and other countries in crisis, noting that the United States had an estimated 30 million unused doses of the AstraZeneca (NASDAQ:AZN) vaccine that is in use elsewhere, but has not been authorized by U.S. regulators.

Washington should also lift export controls on raw materials put in place via the Defense Production Act and an associated export embargo in February, Jha wrote.

White House Press Secretary Jen Psaki on Friday said U.S. and Indian officials were working to find ways to help address the crisis, but gave no timetable for the support.

She said the United States has already provided India some $1.4 billion in health assistance, emergency relief supplies, pandemic training for Indian state and local health officials, and ventilators.

Latest comments

The massive infections and deaths are all the Indian people's own fault after they congregated without protection despite warnings everywhere. It's a well-known fact that there is no cure for stu' pid 'ity.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.